Affiliation:
1. Rostov Regional Clinical Hospital, Rostov-on-Don
2. Rostov State Medical University, Rostov-on-Don
Abstract
Objective:to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.Materials and methods:111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consisted of 25 patients with CHD, CHF II-III FC and thyrotoxicosis; the 1st group of comparison - 30 patients with CHD and CHF II-III FC, without thyrotoxicosis; the 2nd group — 30 patients with thyrotoxicosis without CHD, the 3rd group - 26 patients with thyrotoxicosis and CHD, with no signs of CHF. Te fnding of thyroid gland, the level of NT-proBNP was estimated at baseline and afer 6 months therapy. A new cut-off NT-proBNP for the diagnosis of CHF in comorbid patients was calculated by using ROC analysis.Results:the high concentration of NT-proBNP was detected in all patients (more then 125 pg/ml), in the 2nd comparison group — 225.5 (180.1, 376.1) pg/ml. Te NT-proBNP values in the patients of the 1st and 3rd comparison groups did not differ signifcantly. Te highest level of NT-proBNP was detected in the main group — 712.1 (434.3, 893.9) pg/ml. A cut-off of this marker for screening CHF in comorbid patients with CHD and thyrotoxicosis was calculated - 556.4 pg/ml (a sensitivity of 72 %, a specifcity of 100 %, an accuracy of 87.2 % (p <0.001)). Afer 6 months therapy in the 2nd comparison group the level of NT-proBNP decreased by 74 % (р<0,0001) and has reached the normal value (64,6 (42,2;76,3)); in the main group the level decreased by 43% and was 406,7 (309,1; 498,6) pg/ml.Conclusions:the patients of all groups showed an increased concentration of NT-proBNP. Te highest level of NT-proBNP was observed in the group of patients with CHF by CHD and thyrotoxicosis. Te level of NT-proBNP was determined - 556.4 pg/ml, which allows us to diagnose CHF in patients with a combination of CHD and thyrotoxicosis.
Publisher
Rostov State Medical University
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference21 articles.
1. Larina VN, Chukaeva II. Diagnosis and Treatment of Chronic Heart Failure (based on 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure). Lechebnoe delo (Medical Care, Russian journal). 2016;6:37-48. (in Russ).
2. Mareyev VYU., Fomin IV., Ageyev FT., Arutyunov GP., Begrambekova YUL., Belenkov YUN. at al. Clinical recommendations. Chronic heart failure (CHF). Journal Serdechnaya Nedostatochnost’. 2017;18(1):3–40. (in Russ). doi: 10.18087/rhf.2017.1.2346
3. Fomin IV. Chronic heart failure in the Russian Federation: what we know today and what should be done. Rossiyskiy kardiologicheskiy zhurnal (Russian Cardiology Journal). 2016;(8):7–13. (in Russ). doi:10.15829/1560-4071-2016-8-7-13
4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur Heart J. – 2016. - №37. – С. 2129-2200. DOI:10.1093/eurheartj/ehw128
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;(1):7-81. (In Russ.) doi: 10.15829/1560-4071-2017-1-7-81
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献